AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABCL AbCellera Biologics

Trading 11-15 11:37:17 EST

2.61

-0.15

-5.62%

High2.76	Low2.60	Vol1.36M
Open2.75	D1 Closing2.76	Amplitude5.98%
Mkt Cap767.60M	Tradable Cap491.18M	Total Shares294.67M
T/O3.60M	T/O Rate0.72%	Tradable Shares188.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ABCL","market":"US","secType":"STK","nameCN":"AbCellera Biologics","latestPrice":2.605,"timestamp":1731688636295,"preClose":2.76,"halted":0,"volume":1355711,"delay":0,"floatShares":188552967,"shares":294665532,"eps":-0.609548,"marketStatus":"Trading","change":-0.155,"latestTime":"11-15 11:37:17 EST","open":2.75,"high":2.76,"low":2.595,"amount":3597184.7295426,"amplitude":0.059783,"askPrice":2.61,"askSize":3943,"bidPrice":2.6,"bidSize":7533,"shortable":3,"etf":0,"ttmEps":-0.609548,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1731704400000},"marketStatusCode":2,"adr":0,"listingDate":1607662800000,"exchange":"NASDAQ","adjPreClose":2.76,"preHourTrading":{"tag":"盘前","latestPrice":2.7,"preClose":2.76,"latestTime":"08:44 EST","volume":620,"amount":1694.8149500000002,"timestamp":1731678250743},"postHourTrading":{"tag":"盘后","latestPrice":2.94,"preClose":2.76,"latestTime":"19:41 EST","volume":13355,"amount":36704.0589,"timestamp":1731631265664},"volumeRatio":1.07385,"impliedVol":1.131,"impliedVolPercentile":0.8651},"requestUrl":"/m/hq/s/ABCL","defaultTab":"news","newsList":[{"id":"2481823891","title":"AbCellera presents data on applications of T-cell engager platform at SITC","url":"https://stock-news.laohu8.com/highlight/detail?id=2481823891","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481823891?lang=en_us&edition=fundamental","pubTime":"2024-11-07 23:10","pubTimestamp":1730992215,"startTime":"0","endTime":"0","summary":"AbCellera (ABCL) announced new data on its T-cell engager, or TCE, platform, to be presented as a poster at the Society for Immunotherapy of Cancer...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abcellera-presents-data-on-applications-of-t-cell-engager-platform-at-sitc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abcellera-presents-data-on-applications-of-t-cell-engager-platform-at-sitc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","BK4535","ABCL"],"gpt_icon":0},{"id":"2481167412","title":"AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481167412","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481167412?lang=en_us&edition=fundamental","pubTime":"2024-11-07 23:05","pubTimestamp":1730991900,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, November 07, 2024----AbCellera  today announced new data on its T-cell engager  platform, to be presented as a poster at the Society for Immunotherapy of Cancer  39th Annual Meeting at the George R. Brown Convention Center in Houston, Texas.AbCellera’s presentation, which is available for viewing here, describes:. Strategies to address key challenges in TCE development:. CD3-binding antibodies to widen the therapeutic window by generating TCEs with potent tumor-cell killing and optimal cytokine release. Molecules to enhance efficacy for solid tumor indications by increasing T-cell activation and proliferation through costimulation of CD28 and 4-1BB. Application of the platform to two of AbCellera’s TCE programs:. This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current belie","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Sm4Ot_7GUWiuwnma7JAp.w--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c2e84e927191472ec578af0702ab0e6e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Sm4Ot_7GUWiuwnma7JAp.w--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c2e84e927191472ec578af0702ab0e6e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abcellera-presents-data-applications-t-150500517.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4080","BK4121","SITC","ABCL","BK4535","BK4231"],"gpt_icon":0},{"id":"2481901757","title":"AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481901757","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481901757?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:48","pubTimestamp":1730983735,"startTime":"0","endTime":"0","summary":"The analysts might have been a bit too bullish on AbCellera Biologics Inc. , given that the company fell short of expectations when it released its quarterly results last week. It definitely looks like a negative result overall with revenues falling 19% short of analyst estimates at US$6.5m. Statutory losses were US$0.17 per share, 31% bigger than what the analysts expected. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.Check out our latest analysis for AbCellera Biologics","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/dC75hPkPk1wNzUHQ29Af1A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/dC75hPkPk1wNzUHQ29Af1A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abcellera-biologics-inc-nasdaq-abcl-124855792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","PSQ","IE00B3QW5Z07.USD","ABCL","TQQQ","SQQQ","BK4585","BK4112","QID","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2095319765.USD",".IXIC","NQmain","LU2210150020.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","NDAQ","BK4535","QLD","BK4121","BK4588"],"gpt_icon":1},{"id":"2481608427","title":"AbCellera Biologics Third Quarter 2024 Earnings: Misses Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2481608427","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481608427?lang=en_us&edition=fundamental","pubTime":"2024-11-06 20:10","pubTimestamp":1730895032,"startTime":"0","endTime":"0","summary":"NasdaqGS:ABCL Earnings and Revenue Growth November 6th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 19%. Earnings per share  also missed analyst estimates by 31%.Looking ahead, revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US.The company's shares are down 3.9% from a week ago.You should learn about the   1 warning sign  we've spotted with AbCellera Biologics.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abcellera-biologics-third-quarter-2024-121032057.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ABCL"],"gpt_icon":0},{"id":"2481625682","title":"AbCellera Biologics: Promising Investment with Robust Antibody Platform and Strategic Growth Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2481625682","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481625682?lang=en_us&edition=fundamental","pubTime":"2024-11-06 16:19","pubTimestamp":1730881154,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Puneet Souda has reiterated their bullish stance on ABCL stock, giving a Buy rating yesterday. Puneet Souda has given his ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/abcellera-biologics-promising-investment-with-robust-antibody-platform-and-strategic-growth-plans?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/abcellera-biologics-promising-investment-with-robust-antibody-platform-and-strategic-growth-plans?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","ABCL","BK4121"],"gpt_icon":0},{"id":"2481681960","title":"AbCellera Biologics Price Target Cut to $12.00/Share From $14.00 by Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2481681960","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481681960?lang=en_us&edition=fundamental","pubTime":"2024-11-05 23:57","pubTimestamp":1730822220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ABCL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 05, 2024 10:57 ET (15:57 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SF","ABCL"],"gpt_icon":0},{"id":"1154122669","title":"Stock Track | AbCellera Stock Plunges on Wider Q3 Loss Despite Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1154122669","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154122669?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:38","pubTimestamp":1730817508,"startTime":"0","endTime":"0","summary":"AbCellera Biologics Inc.  saw its stock plummet by 13.49% in pre-market trading on November 5, 2024, following the company's third-quarter financial results. The significant decline came after AbCellera reported a net loss of approximately $51 million for Q3 2024, a substantial increase from the $29 million loss in the same quarter last year.The wider net loss was partly attributed to a non-cash impairment charge of around $32 million related to the discontinuation of the development of next-gen","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ABCL"],"gpt_icon":0},{"id":"2481091915","title":"Abcellera Biologics Inc : Bmo Cuts Target Price to $5 From $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2481091915","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481091915?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:21","pubTimestamp":1730812862,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241105:nFWN3MC1RZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABCL","BK4535","BK4121"],"gpt_icon":0},{"id":"1157360485","title":"Stock Track | AbCellera Biologics Stock Plunges in Pre-Market on Wider Q3 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1157360485","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157360485?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:04","pubTimestamp":1730811858,"startTime":"0","endTime":"0","summary":"AbCellera Biologics Inc.  stock experienced a pre-market plunge of 5.19% on November 5, 2024, following the company's third-quarter 2024 financial results. The significant decline in the stock price can be attributed to a few key factors:. Firstly, AbCellera reported a net loss of approximately $51 million for Q3 2024, a substantial increase from the $29 million loss in the same quarter last year. This wider net loss was partly due to a non-cash impairment charge of around $32 million related to","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | AbCellera Biologics Stock Plunges in Pre-Market on Wider Q3 Loss","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ABCL"],"gpt_icon":0},{"id":"2481030335","title":"Abcellera Biologics Inc : Stifel Cuts Target Price to $12 From $14","url":"https://stock-news.laohu8.com/highlight/detail?id=2481030335","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481030335?lang=en_us&edition=fundamental","pubTime":"2024-11-05 20:46","pubTimestamp":1730810785,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241105:nFWN3MC1ME:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","ABCL","BK4535"],"gpt_icon":0},{"id":"2481362579","title":"Abcellera Biologics Inc : Leerink Partners Cuts Target Price to $7 From $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2481362579","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481362579?lang=en_us&edition=fundamental","pubTime":"2024-11-05 19:09","pubTimestamp":1730804981,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241105:nFWN3MC0W4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","ABCL","BK4535"],"gpt_icon":0},{"id":"2481232215","title":"Abcellera Biologics Inc reports results for the quarter ended in September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2481232215","media":"reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481232215?lang=en_us&edition=fundamental","pubTime":"2024-11-05 15:58","pubTimestamp":1730793526,"startTime":"0","endTime":"0","summary":"Abcellera Biologics Inc reports results for the quarter ended in September 30 - Earnings Summary  Abcellera Biologics Inc ABCL.OQ reported a quarterly adjusted loss of 17 cents per share for the quart","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241105:nL8N3MC0U1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL"],"gpt_icon":0},{"id":"2481099544","title":"AbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights: Navigating Challenges with ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2481099544","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481099544?lang=en_us&edition=fundamental","pubTime":"2024-11-05 15:11","pubTimestamp":1730790680,"startTime":"0","endTime":"0","summary":"Revenue: Approximately $7 million for Q3 2024, consistent with Q3 2023.Research and Development Expenses: Approximately $41 million, $3 million more than last year.Sales and Marketing Expenses: About $3 million, a small reduction from last year.General and Administration Expenses: Approximately $19 million, up from $14 million in Q3 2023.Net Loss: Roughly $51 million for the quarter, compared to a loss of nearly $29 million in the same quarter last year.Earnings Per Share: Loss of $0.17 per share on a basic and diluted basis.Cash and Equivalents: Approximately $670 million at the end of the quarter.Cash Used in Operations: Approximately $100 million for the first nine months of 2024.Total Available Liquidity: Approximately $880 million, including unused government funding.GuruFocus has detected 6 Warning Signs with ABCL.AbCellera Biologics Inc  is on track to file CTA for its first two internal pipeline programs, ABCL635 and ABCL575, by Q2 next year.AbCellera Biologics Inc  reported a ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rZ0H4FYNpr2lpurEYMI5Xg--~B/aD0zNTM7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/c5c37f54ed84908462020e810452c812","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rZ0H4FYNpr2lpurEYMI5Xg--~B/aD0zNTM7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/c5c37f54ed84908462020e810452c812"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abcellera-biologics-inc-abcl-q3-071120036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ABCL"],"gpt_icon":0},{"id":"2481384511","title":"AbCellera Biologics Reports Q3 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2481384511","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481384511?lang=en_us&edition=fundamental","pubTime":"2024-11-05 12:09","pubTimestamp":1730779754,"startTime":"0","endTime":"0","summary":"Abcellera Biologics, Inc. ( ($ABCL) ) has released its Q3 earnings. Here is a breakdown of the information Abcellera Biologics, Inc. presented to i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abcellera-biologics-reports-q3-2024-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abcellera-biologics-reports-q3-2024-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","ABCL","BK4535"],"gpt_icon":0},{"id":"2481198975","title":"AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2481198975","media":"Motley Fool Transcribing","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481198975?lang=en_us&edition=fundamental","pubTime":"2024-11-05 12:00","pubTimestamp":1730779218,"startTime":"0","endTime":"0","summary":"ABCL earnings call for the period ending September 30, 2024.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com/earnings/call-transcripts/2024/11/04/abcellera-biologics-abcl-q3-2024-earnings-call-tra/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_motley_transcript","symbols":["ABCL"],"gpt_icon":0},{"id":"2481597206","title":"TD Cowen Remains a Buy on AbCellera Biologics (ABCL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2481597206","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481597206?lang=en_us&edition=fundamental","pubTime":"2024-11-05 10:25","pubTimestamp":1730773549,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Brendan Smith maintained a Buy rating on AbCellera Biologics (ABCL – Research Report) yesterday. The company’s shares closed yeste...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-remains-a-buy-on-abcellera-biologics-abcl-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-remains-a-buy-on-abcellera-biologics-abcl-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","TD","BK4127","BK4566","BK4535","BK4121","ABCL","BK4585","COWN"],"gpt_icon":0},{"id":"2481645595","title":"AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Misses Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481645595","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481645595?lang=en_us&edition=fundamental","pubTime":"2024-11-05 06:55","pubTimestamp":1730760909,"startTime":"0","endTime":"0","summary":"AbCellera Biologics Inc.  came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -21.43%. A quarter ago, it was expected that this company would post a loss of $0.15 per share when it actually produced a loss of $0.13, delivering a surprise of 13.33%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.AbCellera Biologics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $6.51 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 27.30%. This compares to year-ago revenues of $6.6 million. The company has not been able to beat consensus revenue estimates over the last four quarters.Investors should be mindful of the fact that the outlook for the industry can have a mater","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/AwCmIhR0z9Bg4cEkwuNQjw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/AwCmIhR0z9Bg4cEkwuNQjw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abcellera-biologics-inc-abcl-reports-225509580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ABCL"],"gpt_icon":0},{"id":"1151108196","title":"Stock Track | AbCellera's Q3 Loss Widens Amid Higher Expenses, Revenue Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1151108196","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151108196?lang=en_us&edition=fundamental","pubTime":"2024-11-05 05:33","pubTimestamp":1730755996,"startTime":"0","endTime":"0","summary":"Shares of $AbCellera Biologics$ plunged 9.34% in after-hours trading on November 4th, following the company's disappointing third-quarter results. The biotech firm reported a wider net loss for Q3 2024 as higher expenses overshadowed a slight decline in revenue.For the quarter ended September 30th, AbCellera posted a net loss of $51.1 million or $0.17 per share, compared to a loss of $28.6 million or $0.10 per share in the year-ago period. Total revenue came in at $6.5 million, down 1.4% year-ov","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ABCL"],"gpt_icon":0},{"id":"2481455426","title":"AbCellera Biologics Q3 2024 GAAP EPS $(0.17) Misses $(0.15) Estimate, Sales $6.507M Miss $7.950M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2481455426","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481455426?lang=en_us&edition=fundamental","pubTime":"2024-11-05 05:06","pubTimestamp":1730754386,"startTime":"0","endTime":"0","summary":"AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent.  The company reported quarterly sales of $6.507 million which","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41727265/abcellera-biologics-q3-2024-gaap-eps-0-17-misses-0-15-estimate-sales-6-507m-miss-7-950m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"AbCellera Biologics Q3 2024 GAAP EPS $(0.17) Misses $(0.15) Estimate, Sales $6.507M Miss $7.950M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL"],"gpt_icon":0},{"id":"2481504365","title":"Abcellera Biologics Inc - Qtrly Loss per Share $0.17","url":"https://stock-news.laohu8.com/highlight/detail?id=2481504365","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481504365?lang=en_us&edition=fundamental","pubTime":"2024-11-05 05:05","pubTimestamp":1730754302,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241104:nTUA2Z6TSN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","ABCL","BK4535"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abcellera.com","stockEarnings":[{"period":"1week","weight":0.0147},{"period":"1month","weight":0.0781},{"period":"3month","weight":0.0575},{"period":"6month","weight":-0.2418},{"period":"1year","weight":-0.3907},{"period":"ytd","weight":-0.5166}],"compareEarnings":[{"period":"1week","weight":-0.0038},{"period":"1month","weight":0.0234},{"period":"3month","weight":0.0704},{"period":"6month","weight":0.1207},{"period":"1year","weight":0.3195},{"period":"ytd","weight":0.2483}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.031012},{"month":2,"riseRate":0,"avgChangeRate":-0.132842},{"month":3,"riseRate":0.25,"avgChangeRate":-0.046348},{"month":4,"riseRate":0,"avgChangeRate":-0.173736},{"month":5,"riseRate":0.75,"avgChangeRate":0.016324},{"month":6,"riseRate":0.25,"avgChangeRate":-0.025113},{"month":7,"riseRate":0.5,"avgChangeRate":-0.017447},{"month":8,"riseRate":0.5,"avgChangeRate":-0.084951},{"month":9,"riseRate":0.5,"avgChangeRate":-0.005007},{"month":10,"riseRate":0.5,"avgChangeRate":-0.019108},{"month":11,"riseRate":0.75,"avgChangeRate":0.049287},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.014901}],"exchange":"NASDAQ","name":"AbCellera Biologics","nameEN":"AbCellera Biologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AbCellera Biologics(ABCL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AbCellera Biologics,ABCL,AbCellera Biologics股票,AbCellera Biologics股票老虎,AbCellera Biologics股票老虎国际,AbCellera Biologics行情,AbCellera Biologics股票行情,AbCellera Biologics股价,AbCellera Biologics股市,AbCellera Biologics股票价格,AbCellera Biologics股票交易,AbCellera Biologics股票购买,AbCellera Biologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AbCellera Biologics(ABCL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction